In this episode, Frederick Ruberg, MD, and Mathew Maurer, MD, discuss key topics in cardiac amyloidosis such as the evolving understanding of the epidemiology of the disease, contemporary approaches to diagnosis with an emphasis on noninvasive means, disease course and management of heart failure and conduction disease, as well as the recently approved therapeutics for the two major types of cardiac amyloidosis: light-chain and transthyretin. (Educational grant support is provided by Janssen Oncology.)